Perspectives on improving blood pressure control to reduce the clinical and economic burden of hypertension.
blood pressure
blood pressure measurement modalities
hypertension
hypertension management barriers
single-pill combinations
Journal
Journal of internal medicine
ISSN: 1365-2796
Titre abrégé: J Intern Med
Pays: England
ID NLM: 8904841
Informations de publication
Date de publication:
09 2023
09 2023
Historique:
medline:
15
8
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
ppublish
Résumé
The clinical and economic burden of hypertension is high and continues to increase globally. Uncontrolled hypertension has severe but avoidable long-term consequences, including cardiovascular diseases, which are among the most burdensome and most preventable conditions in Europe. Yet, despite clear guidelines on screening, diagnosis and management of hypertension, a large proportion of patients remain undiagnosed or undertreated. Low adherence and persistence are common, exacerbating the issue of poor blood pressure (BP) control. Although current guidelines provide clear direction, implementation is hampered by barriers at the patient-, physician- and healthcare system levels. Underestimation of the impact of uncontrolled hypertension and limited health literacy lead to low adherence and persistence among patients, treatment inertia among physicians and a lack of decisive healthcare system action. Many options to improve BP control are available or under investigation. Patients would benefit from targeted health education, improved BP measurement, individualized treatment or simplified treatment regimens through single-pill combinations. For physicians, increasing awareness of the burden of hypertension, as well as offering training on monitoring and optimal management and provision of the necessary time to collaboratively engage with patients would be useful. Healthcare systems should establish nationwide strategies for hypertension screening and management. Furthermore, there is an unmet need to implement more comprehensive BP measurements to optimize management. In conclusion, an integrative, patient-focused, multimodal multidisciplinary approach to the management of hypertension by clinicians, payers and policymakers, involving patients, is required to achieve long-term improvements in population health and cost-efficiency for healthcare systems.
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
251-268Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 The Association for the Publication of the Journal of Internal Medicine.
Références
NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-80.
Lamirault G, Artifoni M, Daniel M, Barber-Chamoux N. Resistant hypertension: novel insights. Curr Hypertens Rev. 2019;16:61-72.
Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052-90.
Wierzejska E, Giernaś B, Lipiak A, Karasiewicz M, Cofta M, Staszewski R. A global perspective on the costs of hypertension: a systematic review. Arch Med Sci. 2020;16(5):1078-91.
Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021;18(11):785-802.
Banegas JR, Graciani A, de la Cruz-Troca JJ, León-Muñoz LM, Guallar-Castillón P, Coca A, et al. Achievement of cardiometabolic goals in aware hypertensive patients in Spain: a nationwide population-based study. Hypertension. 2012;60(4):898-905.
Fehr A, Lange C, Fuchs J, Neuhauser H, Schmitz R. Health monitoring and health indicators in Europe. J Health Monit. 2017;2(1):3-21.
Wilkins E, Wilson L, Wickramasinghe K, Bhatnagar P, Leal J, Luengo-Fernandez R, et al. European cardiovascular disease statistics. Brussels: European Heart Network; 2017.
Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control. Circulation. 2016;134(6):441-50.
Leung AA, Bushnik T, Hennessy D, McAlister FA, Manuel DG. Risk factors for hypertension in Canada. Health Rep. 2019;30(2):3-13.
Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). G Ital Cardiol (Rome). 2018;19(11):3-73.
Bibbins-Domingo K, Chertow GM, Coxson PG, Moran A, Lightwood JM, Pletcher MJ, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010;362(7):590-9.
Tyson CC, Appel LJ, Vollmer WM, Jerome GJ, Brantley PJ, Hollis JF, et al. Impact of 5-year weight change on blood pressure: results from the Weight Loss Maintenance trial. J Clin Hypertens (Greenwich). 2013;15(7):458-64.
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension. 2018;71(6):1269-324.
Beevers G, Lip GY, O'Brien E. ABC of hypertension: the pathophysiology of hypertension. BMJ. 2001;322(7291):912-6.
Ruppert V, Maisch B. Genetics of human hypertension. Herz. 2003;28(8):655-62.
Beilin LJ, Puddey IB, Burke V. Lifestyle and hypertension. Am J Hypertens. 1999;12(9):934-45.
Bapolisi A, Maurage P, Pappaccogli M, Georges CMG, Petit G, Balola M, et al. Association between post-traumatic stress disorder and hypertension in Congolese exposed to violence: a case-control study. J Hypertens. 2021;40:685-91.
Marmot M. UCL Institute of Health Equity. Review of social determinants and the health divide in the WHO European Region: final report, Updated reprint 2014. World Health Organization. Regional Office for Europe. https://apps.who.int/iris/handle/10665/108636. 2014.
Marmot M, Goldblatt P, Allen J, et al. Institute of Health Equity. Fair society, healthy lives (The Marmot Review). https://www.instituteofhealthequity.org/resources-reports/fair-society-healthy-lives-the-marmot-review. 2010.
Marmot M. Health equity in England: the Marmot review 10 years on. BMJ. 2020;368:m693.
Hardy ST, Loehr LR, Butler KR, Chakladar S, Chang PP, Folsom AR, et al. Reducing the blood pressure-related burden of cardiovascular disease: impact of achievable improvements in blood pressure prevention and control. J Am Heart Assoc. 2015;4(10):e002276.
Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-67.
Cushman WC. The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression. J Clin Hypertens. 2003;5(3):14-22.
Borghi C, Tubach F, De Backer G, Dallongeville J, Guallar E, Medina J, et al. Lack of control of hypertension in primary cardiovascular disease prevention in Europe: results from the EURIKA study. Int J Cardiol. 2016;218:83-8.
Timmis A, Vardas P, Townsend N, Torbica A, Katus H, De Smedt D, et al. European society of cardiology: cardiovascular disease statistics 2021. Eur Heart J. 2022;43(8):716-99.
Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32(12):2285-95.
Brunström M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(1):28-36.
Blood Pressure Lowering Treatment Trialists’ Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625-36.
Lv J, Ehteshami P, Sarnak MJ, Tighiouart H, Jun M, Ninomiya T, et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ. 2013;185(11):949-57.
Forte G, De Pascalis V, Favieri F, Casagrande M. Effects of blood pressure on cognitive performance: a systematic review. J Clin Med. 2019;9(1):34.
Rea F, Cantarutti A, Merlino L, Ungar A, Corrao G, Mancia G. Antihypertensive treatment in elderly frail patients: evidence from a large Italian database. Hypertension. 2020;76(2):442-9.
Kostova D, Spencer G, Moran AE, Cobb LK, Husain MJ, Datta BK, et al. The cost-effectiveness of hypertension management in low-income and middle-income countries: a review. BMJ Global Health. 2020;5(9):e002213.
Park C, Wang G, Durthaler JM, Fang J. Cost-effectiveness analyses of antihypertensive medicines: a systematic review. Am J Prev Med. 2017;53(6s2):S131-S42.
Chow CK, Teo KK, Rangarajan S, Islam S, Gupta R, Avezum A, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA. 2013;310(9):959-68.
Beaney T, Schutte AE, Tomaszewski M, Ariti C, Burrell LM, Castillo RR, et al. May measurement month 2017: an analysis of blood pressure screening results worldwide. Lancet Glob Health. 2018;6(7):e736-e43.
Imam H, Sundström J, Lind L. Evaluation of time delay between discovery of a high blood pressure in a health screening survey and hypertension diagnosis. Blood Press. 2020;29(6):370-4.
O'Brien E, Asmar R, Beilin L, Imai Y, Mallion J-M, Mancia G, et al. European society of hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens. 2003;21(5):821-48.
Ogedegbe G, Pickering TG, Clemow L, Chaplin W, Spruill TM, Albanese GM, et al. The misdiagnosis of hypertension: the role of patient anxiety. Arch Intern Med. 2008;168(22):2459-65.
Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, et al. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens. 2011;29(3):610-8.
Hilleman DE. Adherence and health care costs with single-pill fixed-dose combinations in hypertension management. J Manag Care Pharm. 2014;20(1):93-100.
Chowdhury R, Khan H, Heydon E, Shroufi A, Fahimi S, Moore C, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J. 2013;34(38):2940-8.
Bitton A, Choudhry NK, Matlin OS, Swanton K, Shrank WH. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med. 2013;126(4):357.e7-357.e27.
Schutte AE, Jafar TH, Poulter NR, Damasceno A, Khan NA, Nilsson PM, et al. Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension. Cardiovasc Res. 2022;119:381-409.
Stergiou GS, Palatini P, Parati G, O'Brien E, Januszewicz A, Lurbe E, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293-302.
Kario K. Nocturnal hypertension: new technology and evidence. Hypertension. 2018;71(6):997-1009.
Fagard RH, Celis H, Thijs L, Staessen JA, Clement DL, De Buyzere ML, et al. Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension. 2008;51(1):55-61.
Banegas JR, Ruilope LM, de la Sierra A, de la Cruz JJ, Gorostidi M, Segura J, et al. High prevalence of masked uncontrolled hypertension in people with treated hypertension. Eur Heart J. 2014;35(46):3304-12.
Parati G, Stergiou G, O'Brien E, Asmar R, Beilin L, Bilo G, et al. European society of hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32(7):1359-66.
de la Sierra A. New American and European hypertension guidelines, reconciling the differences. Cardiol Ther. 2019;8(2):157-66.
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713-9.
Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407.
Sherrill B, Halpern M, Khan S, Zhang J, Panjabi S. Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence. J Clin Hypertens (Greenwich). 2011;13(12):898-909.
Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59(6):1124-31.
Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, et al. Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives. Curr Med Res Opin. 2010;26(9):2065-76.
Belsey JD. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimens. J Med Econ. 2012;15(5):897-905.
Petersen J, Malyutina S, Ryabikov A, Kontsevaya A, Kudryavtsev AV, Eggen AE, et al. Uncontrolled and apparent treatment resistant hypertension: a cross-sectional study of Russian and Norwegian 40-69 year olds. BMC Cardiovasc Disord. 2020;20(1):135.
Ram CV. Fixed-dose triple-combination treatments in the management of hypertension. Manag Care. 2013;22(12):45-55.
Parati G, Kjeldsen SE, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension. Hypertension. 2021;77(2):692-705.
Breitscheidel L, Ehlken B, Kostev K, Oberdiek MS, Sandberg A, Schmieder RE. Real-life treatment patterns, compliance, persistence, and medication costs in patients with hypertension in Germany. J Med Econ. 2012;15(1):155-65.
Xie L, Frech-Tamas F, Marrett E, Baser O. A medication adherence and persistence comparison of hypertensive patients treated with single-, double- and triple-pill combination therapy. Curr Med Res Opin. 2014;30(12):2415-22.
Rea F, Corrao G, Merlino L, Mancia G. Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension. Eur Heart J. 2018;39(40):3654-61.
Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS. Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study. Hypertension. 2013;61(2):309-18.
Benjamin IJ, Kreutz R, Olsen MH, Schutte AE, Lopez-Jaramillo P, Frieden TR, et al. Fixed-dose combination antihypertensive medications. Lancet. 2019;394(10199):637-8.
Mancia G, Kjeldsen SE, Kreutz R, Pathak A, Grassi G, Esler M. Individualized beta-blocker treatment for high blood pressure dictated by medical comorbidities: indications beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension. 2022;79(6):1153-66.
Durand H, Hayes P, Morrissey EC, Newell J, Casey M, Murphy AW, et al. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens. 2017;35(12):2346-57.
Kably B, Billaud EM, Boutouyrie P, Azizi M. Is there any hope for monitoring adherence in an efficient and feasible way for resistant hypertension diagnosis and follow-up? Curr Hypertens Rep. 2020;22(11):96.
Hayes P, Casey M, Glynn LG, Molloy GJ, Durand H, O'Brien E, et al. Prevalence of treatment-resistant hypertension after considering pseudo-resistance and morbidity: a cross-sectional study in Irish primary care. Br J Gen Pract. 2018;68(671):e394-e400.
National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE guideline [NG136]. National Institute for Health and Care Excellence; 2019.
Banegas JR, Lundelin K, de la Figuera M, de la Cruz JJ, Graciani A, Rodríguez-Artalejo F, et al. Physician perception of blood pressure control and treatment behavior in high-risk hypertensive patients: a cross-sectional study. PLoS One. 2011;6(9):e24569.
Volpe M, Dedhiya SD. Physicians, patients, and public knowledge and perception regarding hypertension and stroke: a review of survey studies. Curr Med Res Opin. 2006;22(7):1319-30.
Wexler R, Elton T, Taylor CA, Pleister A, Feldman D. Physician reported perception in the treatment of high blood pressure does not correspond to practice. BMC Fam Pract. 2009;10:23.
Lebeau JP, Cadwallader JS, Aubin-Auger I, Mercier A, Pasquet T, Rusch E, et al. The concept and definition of therapeutic inertia in hypertension in primary care: a qualitative systematic review. BMC Fam Pract. 2014;15:130.
Byrnes PD. Why haven't I changed that? Therapeutic inertia in general practice. Aust Fam Physician. 2011;40(1-2):24-8.
Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, et al. Clinical inertia. Ann Intern Med. 2001;135(9):825-34.
O'Connor PJ, Sperl-Hillen JM, Johnson PE, Rush WA, Biltz G. Advances in patient safety. Clinical inertia and outpatient medical errors. In: Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Advances in patient safety: from research to implementation (Volume 2: concepts and methodology). Rockville (MD): Agency for Healthcare Research and Quality (US); 2005.
Heeley E, Peiris D, Patel A, Cass A, Weekes A, Morgan C, et al. Cardiovascular risk perception and evidence: practice gaps in Australian general practice (the AusHEART study). Med J Aust. 2010;192:254-9.
Petrák O, Zelinka T, Štrauch B, Rosa J, Šomlóová Z, Indra T, et al. Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. J Hum Hypertens. 2016;30(1):35-9.
National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. Clinical guideline [NG136]. National Institute for Health and Care Excellence; 2019. Available at: https://www.nice.org.uk/guidance/ng136 Accessed 8 March 2021.
Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American heart association. Hypertension. 2018;72(5):e53-e90.
Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 2014;114(11):1804-14.
Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International society of hypertension global hypertension practice guidelines. Hypertension. 2020;75(6):1334-57.
Roebuck MC, Liberman JN, Gemmill-Toyama M, Brennan TA. Medication adherence leads to lower health care use and costs despite increased drug spending. Health Aff (Millwood). 2011;30(1):91-9.
Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8(1):e016982.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-87.
Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336(7653):1114-7.
NCD Risk Factor Collaboration. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394(10199):639-51.
Gonzalez A, Pechère-Bertschi A, Burnier M, Schneider M. Medication adherence: the weakest link in blood pressure control. Rev Med Suisse. 2019;15(662):1608-13.
Vrijens B, Antoniou S, Burnier M, de la Sierra A, Volpe M. Current situation of medication adherence in hypertension. Front Pharmacol. 2017;8:100.</bib
Tamblyn R, Abrahamowicz M, Dauphinee D, Wenghofer E, Jacques A, Klass D, et al. Influence of physicians' management and communication ability on patients' persistence with antihypertensive medication. Arch Intern Med. 2010;170(12):1064-72.
Schulz M, Krueger K, Schuessel K, Friedland K, Laufs U, Mueller WE, et al. Medication adherence and persistence according to different antihypertensive drug classes: a retrospective cohort study of 255,500 patients. Int J Cardiol. 2016;220:668-76.
Qvarnström M, Kahan T, Kieler H, Brandt L, Hasselström J, Wettermark B. Medication persistence to antihypertensive drug treatment - a cross-sectional study of attitudes towards hypertension and medication in persistent and non-persistent patients. Blood Press. 2019;28(5):309-16.
Jaeger BC, Bress AP, Bundy JD, Cheung AK, Cushman WC, Drawz PE, et al. Longer-term all-cause and cardiovascular mortality with intensive blood pressure control: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2022;7(11):1138-46.
Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598-605.
Kutner M, Greenberg E, Jin Y, Paulsen C. The health Literacy of America's Adults: Results From the 2003 National Assessment of adult literacy. (NCES 2006-483). U.S. Department of Education. Washington, DC: National Center for Education Statistics. 2006.
Sørensen K, Pelikan JM, Röthlin F, Ganahl K, Slonska Z, Doyle G, et al. Health literacy in Europe: comparative results of the European health literacy survey (HLS-EU). Eur J Public Health. 2015;25(6):1053-8.
Burnier M, Egan BM. Adherence in hypertension. Circ Res. 2019;124(7):1124-40.
Carvalho AS, Santos P. Medication adherence in patients with arterial hypertension: the relationship with healthcare systems' organizational factors. Patient Prefer Adherence. 2019;13:1761-74.
Lane D, Lawson A, Burns A, Azizi M, Burnier M, Jones DJL, et al. Nonadherence in hypertension: how to develop and implement chemical adherence testing. Hypertension. 2022;79(1):12-23.
Menditto E, Cahir C, Aza-Pascual-Salcedo M, Bruzzese D, Poblador-Plou B, Malo S, et al. Adherence to chronic medication in older populations: application of a common protocol among three European cohorts. Patient Prefer Adherence. 2018;12:1975-87.
Mancia G, Zambon A, Soranna D, Merlino L, Corrao G. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J Hypertens. 2014;32(8):1708-15. discussion 16.
Bramlage P, Schmidt S, Sims H. Fixed-dose vs free-dose combinations for the management of hypertension-an analysis of 81 958 patients. J Clin Hypertens (Greenwich). 2018;20(4):705-15.
Poulter NR, Borghi C, Parati G, Pathak A, Toli D, Williams B, et al. Medication adherence in hypertension. J Hypertens. 2020;38(4):579-87.
Świątoniowska-Lonc N, Polański J, Tański W, Jankowska-Polańska B. Impact of satisfaction with physician-patient communication on self-care and adherence in patients with hypertension: cross-sectional study. BMC Health Serv Rese. 2020;20(1):1046.
Petit G, Berra E, Georges CMG, Capron A, Huang QF, Lopez-Sublet M, et al. Impact of psychological profile on drug adherence and drug resistance in patients with apparently treatment-resistant hypertension. Blood Press. 2018;27(6):358-67.
McManus RJ, Little P, Stuart B, Morton K, Raftery J, Kelly J, et al. Home and online management and evaluation of blood pressure (home bp) using a digital intervention in poorly controlled hypertension: randomised controlled trial. BMJ. 2021;372:m4858.
Beaney T, Schutte AE, Stergiou GS, Borghi C, Burger D, Charchar F, et al. May measurement month 2019: the global blood pressure screening campaign of the international society of hypertension. Hypertension. 2020;76(2):333-41.
Rahimi K, Bidel Z, Nazarzadeh M, Copland E, Canoy D, Ramakrishnan R, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397(10285):1625-36.
Park B, Budzynska K, Almasri N, Islam S, Alyas F, Carolan RL, et al. Tight versus standard blood pressure control on the incidence of myocardial infarction and stroke: an observational retrospective cohort study in the general ambulatory setting. BMC Family Practice. 2020;21(1):91.
Mancia G, Facchetti R, Seravalle G, Cuspidi C, Corrao G, Grassi G. Adding home and/or ambulatory blood pressure to office blood pressure for cardiovascular risk prediction. Hypertension. 2021;77(2):640-9.
Ogedegbe G, Schoenthaler A. A systematic review of the effects of home blood pressure monitoring on medication adherence. J Clin Hypertens (Greenwich). 2006;8(3):174-80.
Jo S-H, Kim S-A, Park K-H, Kim H-S, Han S-J, Park W-J. Self-blood pressure monitoring is associated with improved awareness, adherence, and attainment of target blood pressure goals: prospective observational study of 7751 patients. J Clin Hypertens. 2019;21(9):1298-304.
Gradman AH, Basile JN, Carter BL, Bakris GL. Combination therapy in hypertension. J Am Soc Hypertens. 2010;4(1):42-50.
Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23(8):1296-310.
Gerbino PP, Shoheiber O. Adherence patterns among patients treated with fixed-dose combination versus separate antihypertensive agents. Am J Health Syst Pharm. 2007;64(12):1279-83.
Rea F, Savaré L, Franchi M, Corrao G, Mancia G. Adherence to treatment by initial antihypertensive mono and combination therapies. Am J Hypertens. 2021;34(10):1083-91.
Kardas P, Lichwierowicz A, Urbański F, Szadkowska-Opasiak B, Karasiewicz E, Lewek P, et al. The potential to reduce patient co-payment and the public payer spending in poland through an optimised implementation of the generic substitution: the win-win scenario suggested by the real-world big data analysis. Pharmaceutics. 2021;13(8):1165.
Morgan SG, Lee A. Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries. BMJ Open. 2017;7(1):e014287.
Banerjee A, Chen S, Pasea L, Lai AG, Katsoulis M, Denaxas S, et al. Excess deaths in people with cardiovascular diseases during the COVID-19 pandemic. Eur J Prev Cardiol. 2021;28(14):1599-609.
Laffin LJ, Kaufman HW, Chen Z, Niles JK, Arellano AR, Bare LA, et al. Rise in blood pressure observed among US adults during the COVID-19 pandemic. Circulation. 2022;145(3):235-7.
Johansson M, Guyatt G, Montori V. Guidelines should consider clinicians' time needed to treat. BMJ. 2023;380:e072953.
Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-35.
Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keepanasseril A, et al. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2014;2014(11):Cd000011.
Frias J, Virdi N, Raja P, Kim Y, Savage G, Osterberg L. Effectiveness of digital medicines to improve clinical outcomes in patients with uncontrolled hypertension and type 2 diabetes: prospective, open-label, cluster-randomized pilot clinical trial. J Med Internet Res. 2017;19(7):e246.
Tucker KL, Sheppard JP, Stevens R, Bosworth HB, Bove A, Bray EP, et al. Self-monitoring of blood pressure in hypertension: a systematic review and individual patient data meta-analysis. PLoS Med. 2017;14(9):e1002389.
Paterson M, Kinnear M, Bond C, McKinstry B. A systematic review of electronic multi-compartment medication devices with reminder systems for improving adherence to self-administered medications. Int J Pharm Pract. 2017;25(3):185-94.
Thakkar J, Kurup R, Laba TL, Santo K, Thiagalingam A, Rodgers A, et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern Med. 2016;176(3):340-9.
Omboni S, Gazzola T, Carabelli G, Parati G. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013;31(3):455-67. discussion 67-8.
Overwyk KJ, Dehmer SP, Roy K, Maciosek MV, Hong Y, Baker-Goering MM, et al. Modeling the health and budgetary impacts of a team-based hypertension care intervention that includes pharmacists. Med Care. 2019;57(11):882-9.
Gaffari-Fam S, Babazadeh T, Oliaei S, Behboodi L, Daemi A. Adherence to a health literacy and healthy lifestyle with improved blood pressure control in Iran. Patient Prefer Adherence. 2020;14:499-506.
Redon J. The importance of 24-hour ambulatory blood pressure monitoring in patients at risk of cardiovascular events. High Blood Press Cardiovasc Prev. 2013;20(1):13-8.
Sega R, Corrao G, Bombelli M, Beltrame L, Facchetti R, Grassi G, et al. Blood pressure variability and organ damage in a general population. Hypertension. 2002;39(2):710-4.
Flack JM, Nasser SA. Benefits of once-daily therapies in the treatment of hypertension. Vasc Health Risk Manag. 2011;7:777-87.
Brguljan J, Chazova IE, Gaciong Z, Simic D, Vajer P, Zelveian P, et al. Single pill combinations present a proven fast track in practice to reach the target blood pressure. Eur Heart J. 2021;42(Suppl_1):ehab724.2361.
Rea F, Savaré L, Corrao G, Mancia G. Adherence to lipid-lowering treatment by single-pill combination of statin and ezetimibe. Adv Ther. 2021;38(10):5270-85.
Paczkowska-Walendowska M, Sip S, Staszewski R, Cielecka-Piontek J. Single-pill combination to improve hypertension treatment: pharmaceutical industry development. Int J Environ Res Public Health. 2022;19(7):4156.
Gupta P, Patel P, Strauch B, Lai FY, Akbarov A, Maresova V, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69(6):1113-20.
Cappuccio FP, Kerry SM, Forbes L, Donald A. Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ. 2004;329(7458):145.
McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet. 2010;376(9736):163-72.
Schmieder RE, Tschöpe D, Koch C, Ouarrak T, Gitt AK, Avsar S, et al. Individualised treatment targets in patients with type-2 diabetes and hypertension. Cardiovasc Diabetol. 2018;17(1):18.
Ninan SG. Older people need an individualised approach to treating hypertension. BMJ. 2016;353:i2244.
Currie G, Delles C. Use of biomarkers in the evaluation and treatment of hypertensive patients. Curr Hypertens Rep. 2016;18(7):54.
Turner ST, Schwartz GL, Boerwinkle E. Personalized medicine for high blood pressure. Hypertension. 2007;50(1):1-5.
Kucharska A, Gajewska D, Kiedrowski M, Sińska B, Juszczyk G, Czerw A, et al. The impact of individualised nutritional therapy according to DASH diet on blood pressure, body mass, and selected biochemical parameters in overweight/obese patients with primary arterial hypertension: a prospective randomised study. Kardiol Pol. 2018;76(1):158-65.
Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160(1):41-6.
Jeong SM, Kim S, Wook Shin D, Han K, Hyun Park S, Hyuk Kim S, et al. Persistence and adherence to antihypertensive drugs in newly treated hypertensive patients according to initial prescription. Eur J Prev Cardiol. 2020;28:e1-e4.
Dzau VJ, Balatbat CA. Future of hypertension. Hypertension. 2019;74(3):450-7.
Magid DJ, Ho PM, Olson KL, Brand DW, Welch LK, Snow KE, et al. A multimodal blood pressure control intervention in 3 healthcare systems. Am J Manag Care. 2011;17(4):e96-103.
Sheilini M, Hande HM, Prabhu MM, Pai MS, George A. Impact of multimodal interventions on medication nonadherence among elderly hypertensives: a randomized controlled study. Patient Prefer Adherence. 2019;13:549-59.
National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP). Health and economic benefits of high blood pressure interventions. https://www.cdc.gov/chronicdisease/programs-impact/pop/high-blood-pressure.htm Last accessed 20 March 2023.
Machnicki G, Ong SH, Chen W, Wei ZJ, Kahler KH. Comparison of amlodipine/valsartan/hydrochlorothiazide single pill combination and free combination: adherence, persistence, healthcare utilization and costs. Curr Med Res Opin. 2015;31(12):2287-96.
Ferrario CM, Panjabi S, Buzinec P, Swindle JP. Clinical and economic outcomes associated with amlodipine/renin-angiotensin system blocker combinations. Ther Adv Cardiovasc Dis. 2013;7(1):27-39.
Cimmaruta D, Lombardi N, Borghi C, Rosano G, Rossi F, Mugelli A. Polypill, hypertension and medication adherence: the solution strategy? Int J Cardiol. 2018;252:181-6.
Joseph P, Roshandel G, Gao P, Pais P, Lonn E, Xavier D, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021;398(10306):1133-46.
Mackenzie IS, Rogers A, Poulter NR, Williams B, Brown MJ, Webb DJ, et al. Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial. Lancet. 2022;400(10361):1417-25.
Kunz M, Lauder L, Ewen S, Böhm M, Mahfoud F. The current status of devices for the treatment of resistant hypertension. Am J Hypertens. 2020;33(1):10-8.
Lobo MD, Sharp ASP, Kapil V, Davies J, de Belder MA, Cleveland T, et al. Joint UK societies' 2019 consensus statement on renal denervation. Heart. 2019;105(19):1456-63.
Schmieder RE, Mahfoud F, Mancia G, Azizi M, Böhm M, Dimitriadis K, et al. European society of hypertension position paper on renal denervation 2021. J Hypertens. 2021;39(9):1733-41.
Omboni S, McManus RJ, Bosworth HB, Chappell LC, Green BB, Kario K, et al. Evidence and recommendations on the use of telemedicine for the management of arterial hypertension: an international expert position paper. Hypertension. 2020;76(5):1368-83.
Cappuccio FP. The role of nocturnal blood pressure and sleep quality in hypertension management. Eur Cardiol. 2020;15:e60.
Kuwabara M, Harada K, Hishiki Y, Ohkubo T, Kario K, Imai Y. Validation of a wrist-type home nocturnal blood pressure monitor in the sitting and supine position according to the ANSI/AAMI/ISO81060-2:2013 guidelines: Omron HEM-9601T. J Clin Hypertens (Greenwich). 2020;22(6):970-8.
Indraratna P, Tardo D, Yu J, Delbaere K, Brodie M, Lovell N, et al. mHealth interventions in the management of heart failure, ischaemic heart disease and hypertension: a systematic review and meta-analysis of randomised controlled trials. Eur Heart J. 2020;41(Suppl_2):ehaa946.3507.
Torjesen I. Doctors are under more work pressure than during height of Covid-19 pandemic in 2020. BMJ. 2021;375:n3088.
Hayman Laura L, Berra K, Fletcher Barbara J, Houston Miller N. The role of nurses in promoting cardiovascular health worldwide. J Am Coll Cardiol. 2015;66(7):864-6.
Mancia G. Residual risk in treated patients. In: Manual of Hypertension of the European Society of Hypertension. 3rd ed. Milton Park: Taylor & Francis Group; 2019. p. 7.
Piper MA, Evans CV, Burda BU, Margolis KL, O'Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015;162(3):192-204.
Ingabire PM, Ojji DB, Rayner B, Ogola E, Damasceno A, Jones E, et al. High prevalence of non-dipping patterns among Black Africans with uncontrolled hypertension: a secondary analysis of the CREOLE trial. BMC Cardiovasc Disord. 2021;21(1):254.
Ivy JR, Bailey MA. Nondipping blood pressure: predictive or reactive failure of renal sodium handling? Physiology. 2021;36(1):21-34.
Calin P, Viorel M, Luchiana P, Mihaela C, Lavinia P. Masked nocturnal hypertension as a result of high prevalence of non-dippers among apparently well-controlled hypertensive patients with type 2 diabetes mellitus: data from a prospective study. Diabetol Metab Syndr. 2022;14(1):130.
Cuspidi C, Sala C, Tadic M, Gherbesi E, De Giorgi A, Grassi G, et al. Clinical and prognostic significance of a reverse dipping pattern on ambulatory monitoring: an updated review. J Clin Hypertens (Greenwich). 2017;19(7):713-21.
Armitage LC, Davidson S, Mahdi A, Harford M, McManus R, Farmer A, et al. Diagnosing hypertension in primary care: a retrospective cohort study to investigate the importance of night-time blood pressure assessment. Br J Gen Pract. 2023;73(726):e16-e23.
Li Y, Wang J-G. Isolated nocturnal hypertension. Hypertension. 2013;61(2):278-83.
Mulè G, Cottone S. How common is isolated nocturnal hypertension? J Hypertens. 2020;38(3):400-2.
Mancia G, Messerli F, Bakris G, Zhou Q, Champion A, Pepine CJ. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007;50(2):299-305.
Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan alone and in combination with Ramipril Global Endpoint Trial (ONTARGET). Circulation. 2011;124(16):1727-36.
Mancia G, Kjeldsen SE, Zappe DH, Holzhauer B, Hua TA, Zanchetti A, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial. Eur Heart J. 2016;37(12):955-64.
Hata J, Arima H, Rothwell PM, Woodward M, Zoungas S, Anderson C, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation. 2013;128(12):1325-34.
Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375(9718):895-905.
Mancia G, Schumacher H, Bohm M, Redon J, Schmieder RE, Verdecchia P, et al. Relative and combined prognostic importance of on-treatment mean and visit-to-visit blood pressure variability in ONTARGET and TRANSCEND patients. Hypertension. 2017;70(5):938-48.
Wang N, Harris K, Hamet P, Harrap S, Mancia G, Poulter N, et al. Cumulative systolic blood pressure load and cardiovascular risk in patients with diabetes. J Am Coll Cardiol. 2022;80(12):1147-55.
Mancia G, Parati G, Bilo G, Maronati A, Omboni S, Baurecht H, et al. Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. J Hypertens. 2007;25(5):1087-94.
Carey RM, Muntner P, Bosworth HB, Whelton PK. Prevention and control of hypertension. J Am Coll Cardiol. 2018;72(11):1278-93.